Literature DB >> 14625847

Toward the identification of liver toxicity markers: a proteome study in human cell culture and rats.

Birgit Thome-Kromer1, Ines Bonk, Mathias Klatt, Grit Nebrich, Marion Taufmann, Stewart Bryant, Ulrich Wacker, Andreas Köpke.   

Abstract

The effects of toxic and nontoxic compound treatments were investigated by high resolution custom developed 2-11 pH gradient NEPHGE (non equilibrium pH gradient electrophoresis) two-dimensional electrophoresis. Two models were compared: (i) in vivo rat and (ii) the human cell line HepG2, to test their suitability in a proteomics based approach to identify a toxicity marker. 163 and 321 proteins were identified from the rat liver and the HepG2 proteome. These represent various isoforms of 113 and 194 different NCBI annotated gene sequences, respectively. Nine compounds were selected to induce proteome variations associated with liver toxicity and metabolism. The rat liver proteome database consists of 78 gels, the HepG2 database of 52 gels. Variant proteins were assessed regarding their usefulness as a toxicity marker by evaluating their treatment specificity against multiple control treatments. Thirteen potential toxicity marker proteins were found in rat liver and eight in HepG2. Catalase and carbamoylphosphate synthetase-1 isoforms were found to be significantly changed after treatment by 4/4 and 3/4 toxic compounds in rat liver, respectively. Aldo-keto-reductase family 1, member C1 was implicated for 3/4 liver cell toxic compounds in HepG2. Our approach was able to differentiate the quality of potential toxicity markers and provided useful information for an ongoing characterization of more compounds in a wider number of toxicity classes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14625847     DOI: 10.1002/pmic.200300552

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  8 in total

1.  Differential liver protein expression during schistosomiasis.

Authors:  Marina Harvie; Thomas William Jordan; Anne Camille La Flamme
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

2.  Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma.

Authors:  Kok Sun Looi; Ernesto S Nakayasu; Raquel A de Diaz; Eng M Tan; Igor C Almeida; Jian-Ying Zhang
Journal:  J Proteome Res       Date:  2008-08-02       Impact factor: 4.466

3.  Alterations in the rat serum proteome during liver injury from acetaminophen exposure.

Authors:  B Alex Merrick; Maribel E Bruno; Jennifer H Madenspacher; Barbara A Wetmore; Julie Foley; Rembert Pieper; Ming Zhao; Anthony J Makusky; Andrew M McGrath; Jeff X Zhou; John Taylor; Kenneth B Tomer
Journal:  J Pharmacol Exp Ther       Date:  2006-05-10       Impact factor: 4.030

4.  Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics.

Authors:  Libang Yang; Kyle D Rudser; LeeAnn Higgins; Hugo R Rosen; Atif Zaman; Christopher L Corless; Larry David; Glenn R Gourley
Journal:  Dig Dis Sci       Date:  2011-05-17       Impact factor: 3.199

5.  Differential patterns of liver proteins in experimental murine hepatosplenic schistosomiasis.

Authors:  B Manivannan; P Rawson; T W Jordan; W E Secor; A C La Flamme
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

6.  Role of copper,zinc-superoxide dismutase in catalyzing nitrotyrosine formation in murine liver.

Authors:  Jian-Hong Zhu; Xiaomei Zhang; Carol A Roneker; James P McClung; Sheng Zhang; Theodore W Thannhauser; Daniel R Ripoll; Qi Sun; Xin Gen Lei
Journal:  Free Radic Biol Med       Date:  2008-05-28       Impact factor: 7.376

Review 7.  The role of toxicoproteomics in assessing organ specific toxicity.

Authors:  B Alex Merrick; Frank A Witzmann
Journal:  EXS       Date:  2009

8.  Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells.

Authors:  Anja Wilmes; Pisana Rawson; Lifeng Peng; Danyl McLauchlan; Peter T Northcote; T William Jordan; John H Miller
Journal:  Invest New Drugs       Date:  2010-01-27       Impact factor: 3.850

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.